Akero Therapeutics, INC Form 4 insider transactions

Jonathan Young, Chief Operating Officer of Akero Therapeutics, sold shares of the company's common stock on March 4, 2025, according to a recent SEC filing.

Senior VP of Commercial Strategy at Akero Therapeutics, Patrick Lamy, exercised stock options and sold shares on March 3, 2025, according to a recent SEC filing.

Catriona Yale, Chief Development Officer of Akero Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Akero Therapeutics' CEO, Andrew Cheng, executed multiple sales of common stock on February 10, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Director G. Walmsley reports acquiring 200,000 shares of Akero Therapeutics, Inc. at $48 per share on January 30, 2025.

Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, sold shares of common stock on February 5, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Akero Therapeutics' Chief Operating Officer, Jonathan Young, sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Akero Therapeutics' Chief Development Officer, Catriona Yale, executed multiple stock option exercises and sales on January 27, 2025, under a pre-arranged 10b5-1 trading plan.

Akero Therapeutics' Chief Development Officer, Catriona Yale, executed multiple stock transactions, including option exercises and sales, under a pre-arranged 10b5-1 trading plan.

Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, exercised stock options and sold shares on January 27, 2025, under a pre-arranged trading plan.

Senior VP of Commercial Strategy at Akero Therapeutics, Patrick Lamy, reports the acquisition and disposal of company stock and stock options.

Akero Therapeutics CEO Andrew Cheng sold a total of 30,000 shares of common stock on January 27, 2025, under a pre-arranged 10b5-1 trading plan.

Akero Therapeutics' Chief Operating Officer, Jonathan Young, exercised stock options and acquired 43,064 shares of common stock on January 24, 2025.

Akero Therapeutics CEO Andrew Cheng exercised stock options to acquire 50,000 shares of common stock at $0.615 per share.

Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, donated 14,000 shares of common stock to a donor advised fund.

Akero Therapeutics' Chief Operating Officer, Jonathan Young, sold 10,000 shares of common stock at an average price of $28.033, as part of a pre-arranged trading plan.

Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, donated 14,100 shares of common stock to a donor advised fund on December 26, 2024.

Akero Therapeutics' Chief Operating Officer, Jonathan Young, reported the acquisition of restricted stock units and stock options, along with indirect holdings through family trusts.

Senior VP of Commercial Strategy at Akero Therapeutics, Patrick Lamy, reports acquisition of restricted stock units, sale of common stock, and grant of stock options.

Akero Therapeutics' Chief Development Officer, Catriona Yale, engaged in multiple stock transactions, including the vesting of restricted stock units, option exercises, and sales of common stock, as detailed in a recent SEC filing.

Akero Therapeutics' Chief Financial Officer, William Richard White, acquired 24,300 restricted stock units and 73,700 stock options on December 16, 2024.

Akero Therapeutics' Chief Technology Officer, Scott A. Gangloff, acquired 24,300 restricted stock units and 73,700 stock options on December 16, 2024.

Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, engaged in stock transactions, including the exercise of options and sale of shares, under a pre-arranged 10b5-1 trading plan.

Akero Therapeutics CEO Andrew Cheng acquired 98,500 restricted stock units and 295,600 stock options on December 16, 2024.

Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, sold shares to cover tax obligations and exercised stock options, resulting in a net change in his holdings.

Akero Therapeutics' Chief Operating Officer, Jonathan Young, sold 2,503 shares of common stock to cover tax obligations related to vesting restricted stock units.

Akero Therapeutics Senior VP, Commercial Strategy, Patrick Lamy, sold 925 shares of common stock to cover tax obligations related to vesting restricted stock units.

Akero Therapeutics' Chief Development Officer, Catriona Yale, sold 2,810 shares of common stock to cover tax obligations related to vesting restricted stock units.

Akero Therapeutics' Chief Financial Officer, William Richard White, sold 2,817 shares of common stock to cover tax obligations related to vesting restricted stock units.

Akero Therapeutics CEO, Andrew Cheng, sold 7,855 shares of common stock to cover tax obligations related to vesting restricted stock units.